Now enrolling in SUNRAY-01: a Ph3 trial evaluating a next-generation KRAS G12C inhibitor with immunotherapy or chemoimmunotherapy in 1L KRAS G12C-mutant NSCLC.
Click here for patient requirements & trial details: e.lilly/4wZg33q
#LCSM #NSCLC #ClinicalTrials
Click here for patient requirements & trial details: e.lilly/4wZg33q
#LCSM #NSCLC #ClinicalTrials
0:51